Oncorena has started a Phase I/II clinical trial of its drug candidate orellanine to treat individuals with advanced kidney cancer on dialysis.

Orellanine is being developed for organ-specific chemotherapy with curative potential for advanced kidney cancer patients who are undergoing dialysis because of kidney failure. 

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In various preclinical models, orellanine showed to precisely exert great antitumour effects on metastatic kidney cancer.

Carried out at the Centre for Clinical Cancer Studies at Karolinska University Hospital in Stockholm, Sweden, the trial will enrol up to 40 subjects and could include participants from other European nations. 

It will analyse the safety, tolerability, pharmacokinetics, and signs of antitumour effects in treatment with orellanine’s synthetic form.

Subjects will be administered intravenous doses of orellanin in the trial with a dose-escalation part followed by a repeated dose expansion part.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

As the trial subjects are dialysis-dependent, hemodialysis is provided in collaboration with a team at the Karolinska Hospital’s dialysis unit. 

The company noted that the study is being coordinated with a clinical research organisation that focuses on oncology trials.

Oncorena CEO Lars Grundemar said: “There is a great medical need for improved treatment options in patients with advanced kidney cancer undergoing dialysis. 

“We are looking forward to the important clinical development phase in this therapy area. It is our hope that the results from our clinical study will be of great benefit to patients in the future.”

In March last year, the Swedish Medical Products Agency granted approval for the trial of orellanine in patients with advanced kidney cancer undergoing dialysis. 

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact